Literature DB >> 24443268

Relationship of immunohistochemical biomarker expression and lymph node involvement in patients undergoing surgical treatment of NSCLC with long-term follow-up.

Ana María Gómez1, Jose Ramón Jarabo Sarceda, Jose Antonio L García-Asenjo, Cristina Fernandez, Susana Hernandez, Julian Sanz, Elena Fernandez, Joaquin Calatayud, Antonio Torres, Florentino Hernando.   

Abstract

We try to identify the relationship between immunohistochemical marker expression and lymph node involvement in a cohort of 282 patients followed for 5 years after curative resection for NSCLC. In 189 patients (67%), lymph nodes were unaffected while 93 patients (33%) showed nodal involvement. The expression of 15 molecular markers was determined from each patient by tissue-array immunohistochemistry. Univariate analysis indicated significantly higher expression of E-cadherin, γ-catenin, p27, and p53 in patients with lymph node involvement. In those with unaffected nodes, p16 and Rb were expressed. E-cadherin expression was related to a 50% mortality reduction in patients with node involvement (hazard ratio (HR) 0.5; p = 0.017). c-erbB-2 expression was correlated with a 3.4-fold increase in mortality compared to patients without expression of this marker in subjects without node involvement (HR 3.41; p = 0.017). Multivariate analysis identified c-erbB-2 (HR 2.22; p = 0.089) and p27 (HR 1.44; p = 0.019) as prognostics of mortality while Rb (HR 0.74) indicated a good prognosis. The expression of proteins encoded by oncogenes and tumor suppressor genes was different according to lymph node involvement. The increased mortality related to c-erbB-2 expression in patients with unaffected lymph nodes would suggests a need for adjuvant treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24443268     DOI: 10.1007/s13277-013-1599-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  55 in total

1.  [Updated guidelines (1998) for the diagnosis and staging of bronchogenic carcinoma. Work Group of the Spanish Society of Pneumology and Thoracic Surgery].

Authors: 
Journal:  Arch Bronconeumol       Date:  1998-10       Impact factor: 4.872

Review 2.  Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.

Authors:  Sunil Singhal; Anil Vachani; Danielle Antin-Ozerkis; Larry R Kaiser; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

3.  Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival.

Authors:  Tom Donnem; Kenneth Lonvik; Katrine Eklo; Thomas Berg; Sveinung W Sorbye; Khalid Al-Shibli; Samer Al-Saad; Sigve Andersen; Helge Stenvold; Roy M Bremnes; Lill-Tove Busund
Journal:  Cancer       Date:  2011-01-24       Impact factor: 6.860

4.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer.

Authors:  R M Bremnes; R Veve; E Gabrielson; F R Hirsch; A Baron; L Bemis; R M Gemmill; H A Drabkin; W A Franklin
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

5.  Type of resection and prognosis in lung cancer. Experience of a multicentre study.

Authors:  Ramón Rami-Porta; Miquel Mateu-Navarro; Jordi Freixinet; Mercedes de la Torre; Antonio José Torres-García; Yat-Wah Pun; Antonio Cantó Armengod
Journal:  Eur J Cardiothorac Surg       Date:  2005-10       Impact factor: 4.191

6.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.

Authors:  V Esposito; A Baldi; A De Luca; A M Groger; M Loda; G G Giordano; M Caputi; F Baldi; M Pagano; A Giordano
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

7.  Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).

Authors:  Francesco Grossi; Riccardo Spizzo; Domenico Bordo; Veronica Cacitti; Francesca Valent; Ciro Rossetto; Alessandro Follador; Silvia Di Terlizzi; Marianna Aita; Angelo Morelli; Gianpiero Fasola; Clara Consiglieri; Tino Ceschia; Carlo A Beltrami; Ornella Belvedere
Journal:  J Thorac Oncol       Date:  2010-09       Impact factor: 15.609

8.  Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue.

Authors:  M Diez; M Pollán; M Maestro; A Torres; D Ortega; A Gómez; A Sánchez; F Hernando; J L Balibrea
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Prediction of lymph node metastasis by gene expression profiling in patients with primary resected lung cancer.

Authors:  Yasumitsu Moriya; Akira Iyoda; Yasuhiro Kasai; Takashi Sugimoto; Junya Hashida; Yoshinori Nimura; Masaki Kato; Masaki Takiguchi; Takehiko Fujisawa; Naohiko Seki; Ichiro Yoshino
Journal:  Lung Cancer       Date:  2008-10-18       Impact factor: 5.705

10.  Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients.

Authors:  T Nakashima; C Huang; D Liu; K Kameyama; D Masuya; S Kobayashi; M Kinoshita; H Yokomise
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

View more
  3 in total

1.  Development of a nomogram for preoperative prediction of lymph node metastasis in non-small cell lung cancer: a SEER-based study.

Authors:  Chufan Zhang; Qian Song; Lanlin Zhang; Xianghua Wu
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 2.895

2.  HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.

Authors:  Yuan Lu; Yuan Wang; Mi Zhang; Li Liu; Fakai Li; Jian Zhang; Mingxiang Ye; Hu Zhao; Jing Zhao; Bo Yan; Angang Yang; Rui Zhang; Xia Li; Xinling Ren
Journal:  Oncotarget       Date:  2016-04-26

3.  The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer.

Authors:  Zekiye Hasbek; Ömer Tamer Doğan; İsmail Sarı; Birsen Yücel; Mehmet Metin Şeker; Bülent Turgut; Serdar Berk; Yavuz Siliğ
Journal:  Mol Imaging Radionucl Ther       Date:  2016-10-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.